CN1562120A - Medicine for treating nasosinusitis - Google Patents
Medicine for treating nasosinusitis Download PDFInfo
- Publication number
- CN1562120A CN1562120A CN 200410012237 CN200410012237A CN1562120A CN 1562120 A CN1562120 A CN 1562120A CN 200410012237 CN200410012237 CN 200410012237 CN 200410012237 A CN200410012237 A CN 200410012237A CN 1562120 A CN1562120 A CN 1562120A
- Authority
- CN
- China
- Prior art keywords
- gram
- treatment
- grams
- medicine
- bushicao
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating nasosinusitis is prepared from 10 Chinese-medicinal materials including astragalus root, peach kernel, asarum herb, Chuan-xiong rhizome, etc.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of sinusitis, belong to technical field of Chinese medicines.
Background technology
Nasal sinuses is the general name of gassiness bone cavity around the nasal cavity, has 4 pairs, comprises maxillary sinus, sinus frontalis, sieve hole and sphenoid sinus.The hole chamber of pressing the anatomical features maxillary sinus is bigger, the very little position of opening height, and drain is poor, the sickness rate height.But the therapeutic effect of existing medicine is not good, as the bidouyan mixture, bidouyan koufuye that commercially available Tong Junge pharmaceutical factory, Tai Ji group Chongqing produces, its course of treatment long (20 days is a course of treatment), clinically be recommended as 2-3 the course of treatment, medical expense is higher, is lower than medicament provided by the present invention through clinical comparison test obvious effective rate.
Summary of the invention
The invention provides a kind of short treating period, evident in efficacy, medical expense is low, is difficult for the medicine of the pure treatment by Chinese herbs sinusitis of recurrence.
The present invention adopts following scheme to realize, the medicine of treatment sinusitis is characterized in that it is the medicament of being made by the raw material of following weight ratio:
Radix Astragali 10-30 gram cowherb BUSHICAO 6-15 gram Semen Persicae 6-15 gram
The thin 5-10 gram of Flos Magnoliae 6-15 gram Fructus Xanthii 6-15 gram stone Chang
Herba Asari 2-6 gram Rhizoma Chuanxiong 5-15 gram Herba Houttuyniae 3-15 gram Radix Platycodonis 5-10 gram.
The present invention is a kind of medicine for the treatment of sinusitis, and wherein the weight proportion of each raw material is:
Radix Astragali 12-20 gram cowherb BUSHICAO 7-12 gram Semen Persicae 7-12 gram
The thin 7-10 gram of Flos Magnoliae 7-10 gram Fructus Xanthii 7-10 gram stone Chang
Herba Asari 2-4 gram Rhizoma Chuanxiong 7-10 gram Herba Houttuyniae 6-10 gram Radix Platycodonis 6-8 gram.
The present invention is for making curative effect better, and the weight proportion of preferred following raw materials according is:
The Radix Astragali 15 gram cowherb BUSHICAO 10 gram Semen Persicaes 10 grams
Thin 6 grams of Flos Magnoliae 9 gram Fructus Xanthii, 9 gram stone Chang
Herba Asari 3 gram Rhizoma Chuanxiongs 6 gram Herba Houttuyniae 10 gram Radix Platycodoniss 6 grams.
The present invention according to Chinese medicine monarch, minister, help, make and carry out compatibility, monarch drug Radix Astragali benefiting QI for strengthening the superficies in the side, the expelling the toxic substance from the body with tonic skin infection, ingredient L-3 hydroxyl-9-first chlorine stem Lignum pterocarpi indici have antibacterial action, can human body immunity improving power; The Semen Persicae promoting blood circulation to remove blood stasis, contained catechu have vasoconstrictive, reduces the effect of oozing out; The cowherb BUSHICAO can clearing the nasal passage, reaches the sensible effect of QI invigorating detumescence; Contained eugenol in the Flos Magnoliae can play convergence, protection mucosal surface, improves the effect of local circulation; The Fructus Xanthii pain relieving of can detoxifying, eliminating stagnation is sensible, and staphylococcus and bacillus are all had inhibitory action; Thin and the Herba Asari of stone Chang can loose heresy, dry, pain relieving, antihistaminic and the reflection of resistance attitude; Rhizoma Chuanxiong has promoting blood circulation and stopping pain, improves the nose circulation, reduces edema secretions, the effect of anti-proliferation of fibrous tissue; Herba Houttuyniae can detoxify, thereby strengthens the peripheral leukocytic phagocytic activity of human body, human body immunity improving power; The smooth hole antiallergic of Radix Platycodonis evacuation of pus has strengthening vital QI to eliminate pathogenic factors, the effect for the treatment of both the principal and secondary aspects of a disease.
The method for preparing medicine of the present invention:
1, takes by weighing raw material by above-mentioned weight proportion.
2, removal of contamination is used the non-metallic vessel splendid attire.
3, room temperature rinsing 2-3 time.
4, the Radix Astragali, Semen Persicae, cowherb BUSHICAO, stone Chang is thin, Herba Houttuyniae mixes and decocts, and one time 40 minutes, be concentrated to 100-200ml after three times, be mixed in the making sheet and dry naturally with the Flos Magnoliae of pulverizing, Fructus Xanthii, Herba Asari, Rhizoma Chuanxiong, Radix Platycodonis raw material.
5, dry the back and mix pulverizing with Chinese medicine grinder.
6, sieve with 120 orders, incapsulate.
The present invention is as follows through the clinical comparison result of the test:
The treatment group is chosen 130 routine patients and is taken two courses of treatment of medicine of the present invention (the clear relieving capsule of nose) treatment, 10 days each courses of treatment, cure 50 examples (38.46%), produce effects 57 examples (43.85%), effective 16 examples (12.31%), invalid 7 examples (5.38%), total obvious effective rate reaches 82.31%, and total effective rate reaches 94.62%.Each symptom treatment front and back integration situation of change is organized in treatment, sees Table 1.The result shows that treatment each symptom integral of back and total mark value are all than the decline (P<0.001) that highly significant is arranged before the treatment.
Table 1: each symptom integral variation before and after the treatment of treatment group (X ± S)
Symptom | The example number | Before the treatment | After the treatment | The P value |
Nose is cold | ????128 | ?2.73±0.63 | ?0.53±0.65 | ????<0.001 |
Headache | ????102 | ?1.82±0.65 | ?0.54±0.62 | ????<0.001 |
The pus nasal mucus | ????92 | ?1.63±0.61 | ?0.42±0.54 | ????<0.001 |
Hyposmia | ????84 | ?1.57±0.66 | ?0.32±0.56 | ????<0.001 |
Lassitude | ????52 | ?1.54±0.5 | ?0.12±0.32 | ????<0.001 |
Total mark | ????130 | ?7.03±2.37 | ?0.69±0.70 | ????<0.001 |
Matched group is chosen 110 routine patients and is taken medicine of the present invention (the clear relieving capsule of nose), each 2, every day three times, 20 days each courses of treatment, cure 30 examples (27.27%), produce effects 49 examples (44.55%), effective 20 examples (18.18%), invalid 11 examples (10.0%), total obvious effective rate 71.82%, total effective rate reaches 90.00%.Integration situation of change before and after each symptom treatment of matched group sees Table 2.The result shows that treatment each symptom integral of back and total mark value are all than before the treatment significant decline (P<0.001) being arranged.
Table 2: each symptom integral variation before and after the treatment of control group (X ± S)
Symptom | The example number | Before the treatment | After the treatment | The P value |
Nose is cold | ????107 | ?2.26±0.63 | ??0.67±0.71 | ????<0.001 |
Headache | ????93 | ?2.00±0.66 | ??0.67±0.70 | ????<0.001 |
The pus nasal mucus | ????88 | ?1.63±0.63 | ??0.66±0.62 | ????<0.001 |
Hyposmia | ????67 | ?1.54±0.68 | ??0.33±0.59 | ????<0.001 |
Lassitude | ????40 | ?1.40±0.59 | ??0.15±0.43 | ????<0.001 |
Total mark | ????110 | ?7.26±2.80 | ??2.24±2.06 | ????<0.001 |
Treatment group and matched group general curative effect relatively see Table 3.
Table 3: treatment group and matched group general curative effect are relatively
Group | The example number | Cure | Produce effects | Effectively | Invalid | Total obvious effective rate (%) | Total effective rate (%) |
The treatment group | 130 | 50 | 57 | 16 | 7 | 82.31 | 94.62 |
Matched group | 110 | 30 | 49 | 20 | 11 | 71.82 | 90.00 |
Each symptom integral difference relatively sees Table 4 before and after treatment group and the treatment of control group.The result shows that the improvement of symptoms such as the treatment group is cold to nose, headache is better than matched group.
Table 4: each symptom integral difference comparison before and after two groups of treatments (X ± S)
Symptom | The treatment group | Matched group | The P value | ||
The example number | Difference | The example number | Difference | ||
Nose is cold | ??128 | ?1.84±0.78 | ????107 | ?1.59±0.80 | ?<0.05 |
Headache | ??102 | ?1.29±0.75 | ????93 | ?1.42±0.84 | ?<0.05 |
The pus nasal mucus | ??92 | ?1.21±0.75 | ????88 | ?0.97±0.88 | ?<0.05 |
Hyposmia | ??84 | ?1.25±0.67 | ????67 | ?1.21±0.75 | ?<0.05 |
Lassitude | ??52 | ?1.44±0.54 | ????40 | ?1.27±0.55 | ?<0.05 |
Total mark | ??130 | ?5.34±2.54 | ????110 | ?5.02±2.97 | ?<0.05 |
The criterion of above curative effect is: adopt the percentage ratio of sxemiquantitative integration method statistics treatment front and back symptom, sign to change, be divided into level Four.In two courses of treatment, cure: treatment back clinical symptoms, sign disappear, and integration is reduced to " 0 "; Produce effects: treatment back clinical symptoms, sign disappear substantially, and the integration total value reduces 〉=80%; Effectively: treatment back clinical symptoms, sign are improved, and the integration total value reduces 〉=30%, but less than 60%; Invalid: treatment back clinical symptoms, sign do not have significant change, and the integration total value reduces<30%.
The specific embodiment
Embodiment 1
1, press column weight amount proportioning and take by weighing raw material:
The Radix Astragali 15 grams, cowherb BUSHICAO 10 grams, Semen Persicae 10 grams, Flos Magnoliae 9 grams, Fructus Xanthii 9 grams, thin 6 grams of stone Chang, Herba Asari 3 grams, Rhizoma Chuanxiong 6 grams, Herba Houttuyniae 10 grams, Radix Platycodonis 6 grams.
2, removal of contamination is used the non-metallic vessel splendid attire.
3, room temperature rinsing 2-3 time.
4, the Radix Astragali, Semen Persicae, cowherb BUSHICAO, stone Chang is thin, Herba Houttuyniae mixes and boils, and each 40 minutes, be concentrated to 100-200ml after three times, merge medicinal liquid, be mixed in the making sheet and dry naturally with the Flos Magnoliae of pulverizing, Fructus Xanthii, Herba Asari, Rhizoma Chuanxiong, Radix Platycodonis raw material.
5, dry the back and mix pulverizing with Chinese medicine grinder.
6, sieve with 120 orders, incapsulate.
7, medication, three times on the one, a 4-6 grain, warm water delivery service, the child reduces by half, 10 days each courses of treatment.
Embodiment 2
1, presses column weight amount proportioning and take by weighing raw material
The Radix Astragali 10 grams, cowherb BUSHICAO 6 grams, Semen Persicae 6 grams, Flos Magnoliae 6 grams, Fructus Xanthii 6 grams, thin 5 grams of stone Chang, Herba Asari 2 grams, Rhizoma Chuanxiong 5 grams, Herba Houttuyniae 3 grams, Radix Platycodonis 5 grams.
The residue preparation process can be with reference to embodiment 1.
Embodiment 3
1, presses column weight amount proportioning and take by weighing raw material
The Radix Astragali 30 grams, cowherb BUSHICAO 15 grams, Semen Persicae 15 grams, Flos Magnoliae 15 grams, Fructus Xanthii 15 grams, thin 10 grams of stone Chang, Herba Asari 6 grams, Rhizoma Chuanxiong 15 grams, Herba Houttuyniae 15 grams, Radix Platycodonis 10 grams.
The residue preparation process can be with reference to embodiment 1.
Claims (3)
1, a kind of medicine for the treatment of sinusitis is characterized in that it is the medicament of being made by the raw material of following weight ratio:
Radix Astragali 10-30 gram cowherb BUSHICAO 6-15 gram Semen Persicae 6-15 gram
The thin 5-10 gram of Flos Magnoliae 6-15 gram Fructus Xanthii 6-15 gram stone Chang
Herba Asari 2-6 gram Rhizoma Chuanxiong 5-15 gram Herba Houttuyniae 3-15 gram Radix Platycodonis 5-10 gram.
2, the medicine of treatment sinusitis according to claim 1, wherein the weight proportion of each raw material is:
Radix Astragali 12-20 gram cowherb BUSHICAO 7-12 gram Semen Persicae 7-12 gram
The thin 7-10 gram of Flos Magnoliae 7-10 gram Fructus Xanthii 7-10 gram stone Chang
Herba Asari 2-4 gram Rhizoma Chuanxiong 7-10 gram Herba Houttuyniae 6-10 gram Radix Platycodonis 6-8 gram.
3, the medicine of treatment sinusitis according to claim 1, wherein the weight proportion of each raw material is:
The Radix Astragali 15 gram cowherb BUSHICAO 10 gram Semen Persicaes 10 grams
Thin 6 grams of Flos Magnoliae 9 gram Fructus Xanthii, 9 gram stone Chang
Herba Asari 3 gram Rhizoma Chuanxiongs 6 gram Herba Houttuyniae 10 gram Radix Platycodoniss 6 grams.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410012237 CN1225281C (en) | 2004-04-15 | 2004-04-15 | Medicine for treating nasosinusitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410012237 CN1225281C (en) | 2004-04-15 | 2004-04-15 | Medicine for treating nasosinusitis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1562120A true CN1562120A (en) | 2005-01-12 |
CN1225281C CN1225281C (en) | 2005-11-02 |
Family
ID=34477963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410012237 Expired - Fee Related CN1225281C (en) | 2004-04-15 | 2004-04-15 | Medicine for treating nasosinusitis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1225281C (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102614259A (en) * | 2011-06-03 | 2012-08-01 | 宋协勘 | Chinese medicine for treating chronic suppurative nasosinusitis |
CN103393971A (en) * | 2013-08-06 | 2013-11-20 | 秦日香 | Traditional Chinese medicine preparation for nursing patients suffering from rhinitis and preparation method thereof |
CN103638374A (en) * | 2013-11-21 | 2014-03-19 | 山东中大药业有限公司 | Traditional Chinese medicine composition for treating nasosinusitis of equine animals |
CN104523826A (en) * | 2015-01-23 | 2015-04-22 | 李海红 | Medicine for treating nasosinusitis |
CN105362820A (en) * | 2015-12-19 | 2016-03-02 | 许爱美 | Medicine for treating chronic nasosinusitis |
-
2004
- 2004-04-15 CN CN 200410012237 patent/CN1225281C/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102614259A (en) * | 2011-06-03 | 2012-08-01 | 宋协勘 | Chinese medicine for treating chronic suppurative nasosinusitis |
CN103393971A (en) * | 2013-08-06 | 2013-11-20 | 秦日香 | Traditional Chinese medicine preparation for nursing patients suffering from rhinitis and preparation method thereof |
CN103638374A (en) * | 2013-11-21 | 2014-03-19 | 山东中大药业有限公司 | Traditional Chinese medicine composition for treating nasosinusitis of equine animals |
CN103638374B (en) * | 2013-11-21 | 2016-05-25 | 湖南绿亨世源动物药业有限公司 | A kind of Chinese medicine composition for the treatment of equus nasosinusitis |
CN104523826A (en) * | 2015-01-23 | 2015-04-22 | 李海红 | Medicine for treating nasosinusitis |
CN105362820A (en) * | 2015-12-19 | 2016-03-02 | 许爱美 | Medicine for treating chronic nasosinusitis |
Also Published As
Publication number | Publication date |
---|---|
CN1225281C (en) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101259242B (en) | Medicine for treating allergic rhinitis | |
CN1225281C (en) | Medicine for treating nasosinusitis | |
CN1129130A (en) | Medicament for treatment of cervical spondylopathy | |
CN101057942A (en) | External applied medicine ointment for treating diabetes foot and its preparing method | |
CN1324650A (en) | Effective medicine for treating cervical vertebra disease as one kind of intractable disease | |
CN1895593A (en) | Medicine for treating acne and its preparation | |
CN1846781A (en) | Medicine for treating chronic pharyngitis | |
CN1259078C (en) | Chinese medicine for treating women's chronic pelvic infection | |
CN101810749A (en) | Chinese medicament for treating urinary tract infection | |
CN101596297B (en) | Tinea-curing pill | |
CN101181427A (en) | Externally used medicament for curing scaly tetter | |
CN1219527C (en) | Ointment for curing acne and its preparation method | |
CN1939494A (en) | Purge capsules for old person and production thereof | |
CN104587085A (en) | Application of saffron traditional Chinese medicine composition to prepare medicaments treating rhinitis | |
CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
CN1257732C (en) | Medicine for treating mastosis and preparation process thereof | |
CN1256970C (en) | Naristillae for curing rhinopathy | |
CN1112200C (en) | Chinese-medicinal nose drops for treating acute or chronic rhinitis and its preparing process | |
CN102430040A (en) | Medicament for treating diabetes | |
CN1682859A (en) | Chinese medicine for treating rhinitis | |
CN100335099C (en) | Externally applied pure Chinese medicinal tincture for treating manus and pedes tinea | |
CN1065137C (en) | Liniment made of traditional Chinese medicine for treating pharyngitis, and prepn. method therefor | |
CN1899478A (en) | Chinese medicine composition for treating malignant tumor | |
CN1839974A (en) | Medicine composition for treating rheumatoid disease and method for preparing the same | |
CN1739540A (en) | Application of arctiin in preparing medicine for treating rhinitis and nasosinusitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051102 Termination date: 20110415 |